Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FEC3-D3
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FEC3-D3 is a neoadjuvant chemotherapy regimen used primarily for the treatment of node-positive breast cancer. This regimen consists of three cycles of FEC (Fluorouracil, Epirubicin, and Cyclophosphamide) followed by three cycles of Docetaxel. It is designed to provide comparable efficacy with a shorter duration compared to other regimens, aiming to reduce tumor size before surgery and improve patient outcomes. The individual components work through various mechanisms to disrupt cancer cell proliferation and induce cell death.
- Other names
- Neo-shorterFEC-D
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on FEC3-D3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FEC3-D3.